Kath Harrison, Group President, International Growth and General Manager - Dubai, Real Chemistry.Real Chemistry, a global leader in AI- and insights-driven healthcare communications has appointed four senior international leaders to support its global growth strategy.
For the Middle East, Kath Harrison joins as Group President, International Growth. Based in Dubai, she will lead international growth and delivery of end-to-end capabilities across global markets. Harrison will also serve as General Manager of the Dubai office, strengthening Real Chemistry’s presence in the Middle East and its ability to support clients into Asia Pacific and beyond.
The company has also appointed Brandon Pletsch, President, Europe (based in Germany), Louise Clark, President, Integrated Communications, Global (based in UK) and Eleanor Read, President, Integrated Communications, Europe (based in UK).
These updates reflect Real Chemistry’s continued focus on delivering greater consistency, efficiency and seasoned counsel for healthcare clients and brands navigating increasingly complex, multi-market environments.
“Healthcare companies today are operating in a far more complex, multi-market environment, and they need partners who can think and act globally while delivering locally,” said Suzanne Jacobs, Head of International Markets & Group President, Medical Communications.
“By expanding our international leadership and strengthening our regional hub model, we are deepening our ability to support clients across borders — from molecule to market — with the consistency and integrated expertise required to drive meaningful impact worldwide.”
The company’s strategy includes further strengthening its presence across key international markets – including Europe, the Middle East, Asia Pacific and Latin America – through a combination of regional hubs and an expanded affiliate network. Initial investments include new hub offices in Munich, Zurich and Dubai, with additional hub enhancements and in-market team expansion planned later this year.
These leaders bring decades of experience advising global pharmaceutical companies, scaling international agency operations, and building integrated teams across dynamic, regulated markets.
“Real Chemistry was built to solve the unique challenges of healthcare and that focus has become even more critical as our clients operate across increasingly nuanced and interconnected global marketplaces,” said Shankar Narayanan, Chief Executive Officer, Real Chemistry. “By investing in global leadership, regional infrastructure, AI and best-shore capabilities, we are uniquely positioned to deliver expertise, innovative solutions and efficiencies to meet our clients’ needs today and in the future.”
Since 2023, the company’s global team (outside the U.S.) has increased 25 per cent with more than 300 employees currently working in key international markets outside the United States.
This latest strategy update follows Real Chemistry’s recent announcement of RC Resolve, the company’s new healthcare advisory practice. Comprised of some of the industry’s most influential and trusted advisors and leaders, the practice is designed to address healthcare’s most critical business, regulatory and value inflection points where science, business, economics, policy and risk management intersect.
